Our gel AHG crossmatch includes an IS phase. We bill both CPT codes 86920 and 86922, which is allowed. We instituted that with gel implementation in 2007. In April of 2009, following research done by the University of Michigan and in-house validation, we dropped the IS phase in gel but not tube PeG AHG crossmatching. We have reinstuted the IS phase based on the response of the CLIA inspector at the AABB meeting. Our Ortho rep sent us the following: "We are waiting on the response from our company, it is in the works. I would also like to point out that inspecting agencies do not necessarily inform us (manufacturers, transfusion facilities, etc.) ahead of time when they are planning to change how they view certain test applications by any method. Also there can be considerable variation between individual inspectors. OCD cannot 'make sure' they are all covered. Even asking the same question of the inspecting agency today may not make sure all bases are covered for the future. We are very discouraged by all of these changes as well. As soon as I get the official letter, I will make sure you have it. Thank you for your questions and I will pass this along with the other requests for such a letter." I have also asked our LIS vendor, SCC, for confirmation that the SoftBank Version 23.2 does all the system checks for ABO compability when the AHG crossmatch is requested. Currently, our version prompts that the "patient is not eligible for ELXM" when an AHG crossmatch is requested. That response is also pending. You cannot bill ELXM CPT 86923 together with 86922.